| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8485826 | Vaccine | 2018 | 4 Pages |
Abstract
The polio eradication program in Kandahar achieved high serological protection, especially against PV1 and PV3. Lower PV2 seroprevalence in the younger age group is a result of a withdrawal of live type 2 vaccine in 2016 and is expected. Ability to reach all children with poliovirus vaccines is a pre-requisite for achieving poliovirus eradication.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Imtiaz Hussain, Ondrej Mach, Nasir A. Hamid, Zaid S. Bhatti, Deborah D. Moore, M. Steven Oberste, Shahid Khan, Hasan Khan, William C. Weldon, Roland W. Sutter, Zulfiqar A Bhutta, Sajid B. Soofi,